AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma - PubMed
5 hours ago
- #Pancreatic Cancer
- #AI in Medicine
- #Biomarkers
- AI-derived electronic tumor marker (e19-9) developed for CA19-9 nonproducers with pancreatic ductal adenocarcinoma (PDAC).
- Approximately 30% of PDAC patients do not produce elevated CA19-9, necessitating alternative markers.
- Model trained using serum laboratory data from CA19-9 elevated PDAC patients, validated externally.
- Applied to 121 CA19-9 nonproducers with resectable/borderline resectable PDAC receiving neoadjuvant therapy.
- Key cutoffs: ≥50% decline in e19-9 (AUC 0.79) and e19-9 <100 (AUC 0.84) linked to prognosis.
- e19-9 <100 independently associated with overall survival (HR 0.49, P=0.04).
- 77% of patients completed all neoadjuvant therapy and surgery.
- e19-9 offers noninvasive assessment for treatment response in CA19-9 nonproducers.